drugset / Trial / NCT03291366

Mesenchymal Stem Cells in Central Nervous System injury2017

NCT03291366 ↗

Phase 1/2 Unknown 30 enrolled Fuzhou General Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Central nervous system (CNS) injury leads to morbidity in patients, which has few good rehabilitation measures. Mesenchymal stem cells seem to have regenerative and tissue-repairing capabilities. The investigators design this study to infuse mesenchymal stem cells (MSCs) intrathecally to CNS injury patients, and observe the safety and efficacy by recording the change of nervous system scores, trying to prove the effect of MSC in rehabilitate CNS injury.

Timeline

Start
2017-01
Primary completion
2020-01
Completion
2022-01

Drugs

EvaluationDrugModalityDoseRoute
Subject UCMSCC Unknown — Intrathecal

Indications